Australia markets open in 4 hours 32 minutes

C4 Therapeutics, Inc. (CCCC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.9650+0.1250 (+2.58%)
As of 03:28PM EDT. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
20,036
20,756
31,096
45,785
33,195
-
Operating expenses
Research development
111,197
117,706
117,841
94,665
78,440
-
Selling general and administrative
41,424
42,081
42,789
33,254
15,204
-
Total operating expenses
152,621
159,787
160,630
127,919
93,644
-
Operating income or loss
-132,585
-139,031
-129,534
-82,134
-60,449
-
Interest expense
767
1,373
2,216
2,145
1,229
-
Total other income/expenses net
-
-621
-
-
-5,676
325
Income before tax
-124,794
-131,213
-128,175
-83,892
-66,961
-
Income tax expense
1,280
1,280
0
0
-626
-
Income from continuing operations
-126,074
-132,493
-128,175
-83,892
-66,335
-
Net income
-126,074
-132,493
-128,175
-83,892
-66,335
-
Net income available to common shareholders
-126,074
-132,493
-128,175
-83,892
-66,335
-
Basic EPS
-2.75
-
-2.62
-1.82
-5.83
-31.03
Diluted EPS
-2.75
-
-2.62
-1.82
-5.83
-31.03
Basic average shares
49,069
-
48,862
46,042
11,370
1,372
Diluted average shares
49,069
-
48,862
46,042
11,370
1,372